Patients with chronic kidney disease (CKD) are more likely to develop hyperuricemia and gout. Allopurinol and febuxostat are the most commonly used urate-lowering therapies with established safety and efficacy in CKD patients. The objective of the systematic review is to assess the long-term renal outcomes of allopurinol compared with febuxostat in patients with hyperuricemia and CKD or kidney
by H Alatas 2024 Cited by 3CKD both asymptomatic and symptomatic. The recommended drugs for hyperuricemia in CKD are allopurinol and febuxostat. Allopurinol is excreted through the
Allopurinol: Currently recommended as first-line therapy even in patients with moderate-to-severe CKD, allopurinol should be initiated at a
by L Pyne 2024 Cited by 6Trials of allopurinol in patients with more or less proteinuria, or earlier or later stages of CKD will change the baseline risk of CKD
allopurinol to slow the progression of CKD CKD-FIX: Effects of Allopurinol on the Progression of Chronic Kidney Disease.
by S Alobaidi 2024 Cited by 2prescription of allopurinol in CKD patients. Settings and Design: This was a retrospective study of adult patients prescribed allopur- inol with CKD (stages
by A Tiku 2024The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial : PO0587. Tiku
1: Evaluation of CKD. S196. Chapter 2: Risk allopurinol, benzbromarone, febuxostat allopurinol, benzbromarone, febuxostat, oxipurinol
CKD stage 3 to 5 in order to prevent CKD progression or Allopurinol has been commonly used for over 50 years. However, adverse
Comments